LBRX
LB Pharmaceuticals Inc
NasdaqGMUSDEQUITY
DELAYED
Last price
47.62
▲ 0.39 (0.83%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
47.25
Prev close
47.23
Day high
48.18
Day low
46.34
Volume
224.15K
Market cap
—
P/E (TTM)
—
52W range
13.36 – 49.97
Trailing performance
Returnvs SPY
1W
-0.32%
+1.0%
1M
+37.55%
+33.8%
3M
+70.07%
+67.0%
6M
+100.93%
+89.9%
YTD
+113.93%
+101.6%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on LBRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $16.74M | $51.17M | $7.84M | $1.35M | -67.3% |
| Selling, general & admin | $13.66M | $13.66M | $3.53M | $1.46M | +0.0% |
| Total operating expense | $30.40M | $64.83M | $11.38M | $2.81M | -53.1% |
| Operating income | -$30.40M | -$64.83M | -$11.38M | -$2.81M | +53.1% |
| Net interest income | $3.92M | $1.72M | -$4.01M | -$2.08M | +127.8% |
| Pre-tax income | -$25.20M | -$63.10M | -$6.27M | -$14.35M | +60.1% |
| Tax provision | $1.00K | $1.00K | $1.00K | $1.00K | 0.0% |
| Net income | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Net income to common | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Basic EPS | -3.13 | -17.82 | -1.77 | -4.05 | +82.4% |
| Diluted EPS | -3.13 | -17.82 | -1.77 | -4.05 | +82.4% |
| EBIT | -$30.40M | -$64.83M | -$1.45M | -$12.20M | +53.1% |
| EBITDA | -$30.08M | -$64.74M | -$1.45M | -$12.19M | +53.5% |
| Basic shares | 8.05M | 3.54M | 3.54M | 3.54M | +127.2% |
| Diluted shares | 8.05M | 22.44M | 22.44M | 22.44M | -64.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $250.17M | $22.98M | $14.98M | $21.40M | +988.8% |
| Cash & short-term investments | $295.21M | $28.00M | $43.29M | $21.40M | +954.4% |
| Total current assets | $308.43M | $28.88M | $45.63M | $21.49M | +968.0% |
| Property, plant & equipment | $3.73M | $4.16M | $23.00K | $3.00K | -10.2% |
| Total assets | $312.93M | $33.53M | $45.66M | $21.49M | +833.2% |
| Total current liabilities | $7.44M | $8.11M | $2.61M | $469.00K | -8.2% |
| Long-term debt | — | — | — | $24.15M | — |
| Total debt | $3.57M | $3.70M | $0 | $24.15M | -3.6% |
| Total liabilities | $11.62M | $128.09M | $80.13M | $50.30M | -90.9% |
| Retained earnings | -$129.53M | -$104.32M | -$41.22M | -$34.95M | -24.2% |
| Shareholder equity | $301.31M | -$94.55M | -$34.47M | -$28.81M | +418.7% |
| Working capital | $300.99M | $20.77M | $43.03M | $21.02M | +1,349.2% |
| Net tangible assets | $301.31M | -$94.55M | -$34.47M | -$28.81M | +418.7% |
| Shares issued | 25.30M | 22.44M | 22.44M | 22.44M | +12.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$25.20M | -$63.10M | -$6.28M | -$14.35M | +60.1% |
| Depreciation & amortisation | $321.00K | $91.00K | $4.00K | $2.00K | +252.7% |
| Stock-based compensation | $4.19M | $3.16M | $295.00K | $431.00K | +32.6% |
| Change in working capital | -$13.65M | $3.31M | -$1.31M | $86.00K | -512.0% |
| Operating cash flow | -$35.21M | -$53.05M | -$12.09M | -$2.73M | +33.6% |
| Capital expenditure | -$52.00K | -$769.00K | -$25.00K | — | +93.2% |
| Investing cash flow | -$39.89M | $23.23M | -$28.01M | $123.00K | -271.7% |
| Financing cash flow | $302.56M | $38.31M | $33.68M | $22.96M | +689.7% |
| Free cash flow | -$35.26M | -$53.82M | -$12.12M | -$2.73M | +34.5% |
| End cash position | $250.94M | $23.48M | $14.98M | $21.40M | +968.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $14.64M | $8.48M | $2.42M | $2.42M | $3.42M | +72.6% |
| Selling, general & admin | $7.46M | $5.39M | $2.83M | $2.44M | $3.01M | +38.5% |
| Total operating expense | $22.10M | $13.87M | $5.25M | $4.86M | $6.43M | +59.4% |
| Operating income | -$22.10M | -$13.87M | -$5.25M | -$4.86M | -$6.43M | -59.4% |
| Net interest income | $2.85M | $2.80M | $707.00K | $177.00K | $236.00K | +1.8% |
| Pre-tax income | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -66.1% |
| Tax provision | $0 | $1.00K | $0 | $0 | $0 | -100.0% |
| Net income | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -66.1% |
| Net income to common | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -66.1% |
| Basic EPS | -0.67 | -0.45 | -0.61 | — | -0.24 | -48.9% |
| Diluted EPS | -0.67 | -0.45 | -0.61 | — | -0.24 | -48.9% |
| EBIT | -$22.10M | -$13.87M | -$5.25M | -$4.86M | -$6.43M | -59.4% |
| EBITDA | -$22.02M | -$13.79M | -$5.17M | -$4.78M | -$6.35M | -59.8% |
| Basic shares | 28.24M | 25.41M | 5.81M | — | 22.44M | +11.2% |
| Diluted shares | 28.24M | 25.41M | 5.81M | — | 22.44M | +11.2% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $320.68M | $250.17M | $269.74M | $14.22M | $22.98M | +28.2% |
| Cash & short-term investments | $365.64M | $295.21M | $314.48M | $14.22M | $28.00M | +23.9% |
| Total current assets | $389.07M | $308.43M | $316.40M | $14.78M | $28.88M | +26.1% |
| Property, plant & equipment | $3.63M | $3.73M | $3.83M | $3.96M | $4.16M | -2.7% |
| Total assets | $393.48M | $312.93M | $320.75M | $19.25M | $33.53M | +25.7% |
| Total current liabilities | $10.91M | $7.44M | $6.65M | $3.91M | $8.11M | +46.5% |
| Total debt | $3.47M | $3.57M | $3.67M | $3.76M | $3.70M | -2.8% |
| Total liabilities | $14.79M | $11.62M | $10.53M | $123.12M | $128.09M | +27.2% |
| Retained earnings | -$148.58M | -$129.53M | -$118.06M | -$114.50M | -$104.32M | -14.7% |
| Shareholder equity | $378.69M | $301.31M | $310.22M | -$103.87M | -$94.55M | +25.7% |
| Working capital | $378.17M | $300.99M | $309.75M | $10.88M | $20.77M | +25.6% |
| Net tangible assets | $378.69M | $301.31M | $310.22M | -$103.87M | -$94.55M | +25.7% |
| Shares issued | 28.67M | 25.30M | 25.30M | 22.44M | 22.44M | +13.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | — | -66.1% |
| Depreciation & amortisation | $82.00K | $85.00K | $81.00K | $76.00K | $79.00K | — | -3.5% |
| Stock-based compensation | $2.57M | $2.34M | $881.00K | $335.00K | $634.00K | — | +9.6% |
| Change in working capital | -$6.75M | -$9.53M | -$97.00K | -$1.25M | -$2.77M | — | +29.2% |
| Operating cash flow | -$23.29M | -$18.10M | -$3.37M | -$5.60M | -$8.13M | — | -28.7% |
| Capital expenditure | -$32.00K | -$40.00K | — | — | -$21.00K | -$238.00K | +20.0% |
| Investing cash flow | -$32.00K | -$40.00K | -$44.84M | $9.00K | $4.98M | — | +20.0% |
| Financing cash flow | $93.83M | -$1.17M | $303.73M | $0 | $0 | — | +8,119.7% |
| Free cash flow | -$23.32M | -$18.14M | -$3.37M | -$5.59M | -$8.15M | — | -28.5% |
| End cash position | $321.45M | $250.94M | $270.26M | $14.73M | $20.33M | — | +28.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
46.74
+1.88% from price
SMA 20
44.31
+7.48% from price
SMA 50
36.79
+29.45% from price
SMA 100
32.93
+44.61% from price
SMA 200
27.06
+75.96% from price
EMA 12
46.19
+3.09% from price
EMA 26
42.78
+11.31% from price
EMA 50
38.78
+22.79% from price
RSI (14)
65.1
Neutral
MACD (12,26,9)
3.41
Hist -0.09
ATR (14)
2.69
5.66% of price
Realised vol 30D
67.2%
Annualised
Bollinger upper
52.66
20, 2σ
Bollinger lower
35.95
20, 2σ
50 / 200 cross
Golden
36.79 vs 27.06
Trend bias
Above 200
+75.96%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.57
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
67.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-17.8%
Peak to trough
Max drawdown 5Y
-17.8%
Peak to trough
ATR 14
2.69
5.66% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
LB Pharmaceuticals Q2 Loss Per Share Narrows
MT Newswires · 12d ago
LB Pharmaceuticals Inc.: Q2 Earnings Snapshot
Associated Press · 12d ago
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 12d ago
LB Pharmaceuticals Announces $150 Million Private Placement
GlobeNewswire · 25d ago
LB Pharmaceuticals Expects Phase-3 Schizophrenia Study's Topline Data in H1 2027
MT Newswires · 32d ago
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
GlobeNewswire · 32d ago
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
The Fly · 33d ago
BMO Capital Initiates LB Pharmaceuticals at Outperform With $46 Price Target
MT Newswires · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.